Aroosha Sarrafi tells Health her story of getting diagnosed with metabolic dysfunction-associated steatohepatitis (MASH), a ...

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...

Because nothing tests your patience — or your posture — like youth sports season. NEW YORK , NY May 6, 2025 With Mother's Day ...

Use of the investigational drug efruxifermin did not significantly reduce fibrosis in patients with compensated cirrhosis ...

How a commonly “silent disease” is driving urgency and novelty in the liver disease treatment paradigm and what can we hope ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look ...

Target RWE, a leader in modern clinical evidence generation for complex diseases, today announced its presentations and strategic contributions at the EASL Congress 2025 in Amsterdam, Netherlands.

It took a month, but this is the Phillies lineup that was advertised. They pounded the Rays on Wednesday to with their fourth ...

Even the most lauded chefs sometimes can’t be bothered to cook. Here are their pantry staples, from Old El Paso fajitas to ...